Efficacy

PROVEN EFFECTIVE1
Galliprant® (grapiprant tablets) treatment resulted in statistically significant improvements in veterinary assessments and pain interference and pain severity scores compared to placebo on days 7, 14, 21 and 28.*1
  • Prospective, randomized, masked, placebo-controlled, 16-site study
  • Galliprant dosed at 2 mg/kg once daily for 28 days
  • 285 dogs enrolled
  • Dogs receiving Galliprant were 2 to 16.75 years old, weighing 9 to 131 pounds
  • Placebo tablet size and shape matched to Galliprant tablets
  • Validated owner assessment: Canine Brief Pain Inventory (CBPI)** on days 0, 7, 14, 21, 28
  • Veterinary assessment (total orthopedic scores) at screening and on days 14 and 28
Husky
Galliprant represents a promising treatment modality for the pain
and inflammation associated with osteoarthritis (OA) in dogs.1
*Primary study endpoint.

**The CBPI is a validated questionnaire that asks dog owners four questions about the severity of pain evident in a dog (the pain severity score) and six questions about how pain interferes with a dog’s activity level (the pain interference score). The questionnaire also has one overall impression score and is useful in detecting changes in a dog’s condition that result from intervention (e.g., medication, surgery).

Indication

Galliprant is an NSAID indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Important Safety Information

Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.